Induction of p53-independent apoptosis by a novel synthetic hexahydrocannabinol analog is mediated via Sp1-dependent NSAID-activated gene-1 in colon cancer cells

Biochemical Pharmacology

Volumn 80, Issue 1, 2010, Pages 62-71

  Thapa, Dinesh ^a   Babu, Dinesh ^a   Park, Min A ^a   Kwak, Mi Kyoung ^a   Lee, Yong Rok ^a   Kim, Jeong Min ^b   Kwon, Taeg Kyu ^c   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

^b Green Cross Company   (South Korea)

^c Keimyung University   (South Korea)

Author keywords

Colon cancer; Hexahydrocannabinol; NAG 1; P53; Sp1

Indexed keywords

1 (1 HYDROXY 6,6,9 TRIMETHYL 6A,7,8,9,10,10A HEXAHYDRO 6H BENZO[C]CHROMEN 2 YL)ETHANONE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOL DERIVATIVE; DOXORUBICIN; LYR 8; MITHRAMYCIN; MITHRAMYCIN A; PIFITHRIN ALPHA; PROTEIN NAG 1; PROTEIN P53; SMALL INTERFERING RNA; SULINDAC SULFIDE; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL STRAIN HCT116; CELL STRAIN HT29; COLON CANCER; CONTROLLED STUDY; DRUG BINDING SITE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; WILD TYPE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOTHIAZOLES; COLONIC NEOPLASMS; GENES, P53; HCT116 CELLS; HT29 CELLS; HUMANS; PROTEIN KINASES; SULINDAC; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77952293603     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.03.008     Document Type: Article

References (48)

1. Baek S.J., Horowitz J.M., Eling T.E. Molecular cloning and characterization of human nonsteroidal anti-inflammatory drug-activated gene promoter. Basal transcription is mediated by Sp1 and Sp3. J Biol Chem 2001, 276:33384-33392.
2. Shim M., Eling T.E. Vitamin E succinate induces NAG-1 expression in a p38 kinase-dependent mechanism. Mol Cancer Ther 2008, 7:961-971.
3. Baek S.J., Kim K.S., Nixon J.B., Wilson L.C., Eling T.E. Cyclooxygenase inhibitors regulate the expression of a TGF-β superfamily member that has proapoptotic and antitumorigenic activities. Mol Pharmacol 2001, 59:901-908.
4. Baek S.J., Okazaki R., Lee S.H., Martinez J., Kim J.S., Yamaguchi K., et al. Nonsteroidal anti-inflammatory drug-activated gene-1 over expression in transgenic mice suppresses intestinal neoplasia. Gastroenterology 2006, 131:1553-1560.
5. Baek S.J., Kim J., Nixon J.B., DiAugustine R.P., Eling T.E. Expression of NAG-1, a transforming growth factor-β superfamily member, by troglitazone requires the early growth response gene EGR-1. J Biol Chem 2004, 279:6883-6892.
6. Baek S.J., Wilson L.C., His L.C., Eling T.E. Troglitazone, a peroxisome proliferator-activated receptor γ (PPARγ) ligand, selectively induces the early growth response-1 gene independently of PPARγ. A novel mechanism for its anti-tumorigenic activity. J Biol Chem 2003, 278:5845-5853.
7. Yamaguchi K., Lee S.H., Eling T.E., Baek S.J. A novel peroxisome proliferator-activated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 2006, 5:1352-1361.
8. Yamaguchi K., Lee S.H., Eling T.E., Baek S.J. Identification of nonsteroidal anti-inflammatory drug-activated gene (NAG-1) as a novel downstream target of phosphatidylinositol 3-kinase/AKT/GSK-3beta pathway. J Biol Chem 2004, 279:49617-49623.
9. Baek S.J., Wilson L.C., Eling T.E. Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53. Carcinogenesis 2002, 23:425-434.
10. Lee S.H., Kim J.S., Yamaguchi K., Eling T.E., Baek S.J. Indole-3-carbinol and 3,3′-diindolylmethane induce expression of NAG-1 in a p53-independent manner. Biochem Biophys Res Commun 2005, 328:63-69.
11. Lee S.H., Yamaguchi K., Kim J.S., Eling T.E., Safe S., Park Y., et al. Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner. Carcinogenesis 2006, 27:972-981.
12. Baek S.J., Kim J.S., Jackson F.R., Eling T.E., McEntee M.F., Lee S.H. Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells. Carcinogenesis 2004, 25:2425-2432.
13. Li P.X., Wong J., Ayed A., Ngo D., Brade A.M., Arrowsmith C., et al. Placental transforming growth factor-B is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 2000, 275:20127-20135.
14. Tan M., Wang Y., Guan K., Sun Y. PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway. Proc Natl Acad Sci U S A 2000, 97:109-114.
15. Grady W.M., Markowitz S.D. Genetic and epigenetic alterations in colon cancer. Annu Rev Genomics Hum Genet 2002, 3:101-128.
16. Piomelli D., Giuffrida A., Calignano A., Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000, 21:218-224.
17. Porter A.C., Felder C.C. The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther 2001, 90:45-60.
18. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003, 3:745-755.
19. Alexander A., Smith P.F., Rosengren R.J. Cannabinoids in the treatment of cancer. Cancer Lett 2009, 285:6-12.
20. Patsos H.A., Hicks D.J., Greenhough A., Williams A.C., Paraskeva C. Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc Trans 2005, 33:712-714.
21. Sarfaraz S., Adhami V.M., Syed D.N., Afaq F., Mukhtar H. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68:339-342.
22. 2 receptor: a new target for controlling neural cell survival?. Trends Pharmacol Sci 2007, 28:39-45.
23. Pertwee R.G. Pharmacological actions of cannabinoids. Handb Exp Pharmacol 2005, 168:1-51.
24. 2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000, 165:373-380.
25. Thomas B.F., Gilliam A.F., Burch D.F., Roche M.J., Seltzman H.H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J Pharmacol Exp Ther 1998, 285:285-292.
26. Massi P., Vaccani A., Ceruti S., Colombo A., Abbracchio M.P., Parolaro D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J Pharmacol Exp Ther 2004, 308:838-845.
27. Ramer R., Merkord J., Rohde H., Hinz B. Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. Biochem Pharmacol 2010, 79:955-966.
28. Lee Y.R., Xia L. Efficient one-pot synthetic approaches for the cannabinoid analogues and their application to biologically interesting (-)-hexahydrocannabinol and (+)-hexahydrocannabinol. Tetrahedron Lett 2008, 49:3283-3287.
29. Thapa D., Lee J.S., Park S.Y., Bae Y.H., Bae S.K., Kwon J.B., et al. Clotrimazole ameliorates intestinal inflammation and abnormal angiogenesis by inhibiting interleukin-8 expression through a nuclear factor-kappaB-dependent manner. J Pharmacol Exp Ther 2008, 327:353-364.
30. Carmichael J., Degraff W.G., Gazdar A.F., Minna J.D., Mitchell J.B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 1987, 15:936-942.
31. Lim J.H., Park J.W., Min D.S., Chang J.S., Lee Y.H., Park Y.B., et al. NAG-1 up-regulation mediated by EGR-1 and p53 is critical for quercetin-induced apoptosis in HCT116 colon carcinoma cells. Apoptosis 2007, 12:411-421.
32. Kim J.B., Wright H.M., Wright M., Spiegelman B.M. ADD1/SREBP1 activates PPARgamma through the production of endogenous ligand. Proc Natl Acad Sci U S A 1998, 95:4333-4337.
33. Baek S.J., Kim J.S., Moore S.M., Lee S.H., Martinez J., Eling T.E. Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein. Mol Pharmacol 2005, 67:356-364.
34. Baek S.J., Eling T.E. Changes in gene expression contribute to cancer prevention by COX inhibitors. Prog Lipid Res 2006, 45:1-16.
35. Baek S.J., Wilson L.C., Lee C.H., Eling T.E. Dual function of nonsteroidal anti-inflammatory drugs (NSAIDs): inhibition of cyclooxygenase and induction of NSAID-activated gene. J Pharmacol Exp Ther 2002, 301:1126-1131.
36. Chen Y.L., Lin P.C., Chen S.P., Lin C.C., Tsai N.M., Cheng Y.L., et al. Activation of nonsteroidal anti-inflammatory drug-activated gene-1 via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase revealed a isochaihulactone-triggered apoptotic pathway in human lung cancer A549 cells. J Pharmacol Exp Ther 2007, 323:746-756.
37. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
38. Loev B., Bender P.E., Dowalo F., Macko E., Fowler P.J. Cannabinoids. Structure-activity studies related to 1,2-dimethylheptyl derivatives. J Med Chem 1973, 16:1200-1206.
39. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002, 54:161-202.
40. Blazquez C., Casanova M.L., Planas A., Gomez Del Pulgar T., Villanueva C., Fernandez-Acenero M.J., et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 2003, 17:529-531.
41. De Siervi A., Marinissen M., Diggs J., Wang X.-F., Pages G., Senderowicz A. Transcriptional activation of p21waf1/cip1 by alkylphospholipids: role of the mitogen-activated protein kinase pathway in the transactivation of the human p21waf1/cip1 promoter by Sp1. Cancer Res 2004, 64:743-750.
42. Choi B.H., Kim C.G., Bae Y.S., Lim Y., Lee Y.H., Shin S.Y. p21 Waf1/Cip1 expression by curcumin in U-87MG human glioma cells: role of early growth response-1 expression. Cancer Res 2008, 68:1369-1377.
43. Aas T., Borresen A.L., Geisler S., Smith-Sorensen B., Johnsen H., Varhaug J.E., et al. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Med 1996, 2:811-814.
44. Levine A.J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88:323-331.
45. Aneja R., Ghaleb A.M., Zhou J., Yang V.W., Joshi H.C. p53 and p21 determine the sensitivity of noscapine-induced apoptosis in colon cancer cells. Cancer Res 2007, 67:3862-3870.
46. Iguchi G., Chrysovergis K., Lee S.H., Baek S.J., Langenbach R., Eling T.E. A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and cyclooxygenase-2. Cancer Lett 2009, 282:152-158.
47. Bottone F.G., Baek S.J., Nixon J.B., Eling T.E. Diallyl disulfide (DADS) induces the antitumorigenic NSAID-activated gene (NAG-1) by a p53-dependent mechanism in human colorectal HCT 116 cells. J Nutr 2002, 132:773-778.
48. Wilson L.C., Baek S.J., Call A., Eling T.E. Nonsteroidal anti-inflammatory drug-activated gene (NAG-1) is induced by genistein through the expression of p53 in colorectal cancer cells. Int J Cancer 2003, 105:747-753.